STRIDE Study

Trial of a new medication in people with type 1 diabetes aged 18-45 and within 100 days of diagnosis

A 12-month, randomized, single-blind, placebo-controlled exposure- response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

Status: Paused to recruitment until mid 2025.

To join this research study, you must:

• Be aged 18 – 45 years
• Diagnosed  with type 1 diabetes in the last 100 days
• Positive for at least 1 diabetes related autoantibody
• Using insulin as part of standard care

Location: Cambridge Clinical Research Centre on Keith Day Road, next to the Addenbrooke’s Treatment Centre, and part of the Cambridge Biomedical Centre.

Find out more
Email: Jane Kennet